Poland· PL-100455271
Koselugo
A selumetinib product containing selumetinibum, registered in Poland by AstraZeneca AB. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Selumetinib is registered in 16 of 19 countries.
Countries holding a registration under ATC L01EE04 (selumetinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Selumetinib · ATC L01EE04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of selumetinib costs, country by country.
Normalised to the WHO defined daily dose (50 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Selumetinib · price per daily dose (50 mg)
USD · FX 28 Sept 2026
- CH Switzerland$482.52
The record
At a glance
URPL (Poland)- Active substance
- Selumetinibum
- Manufacturer
- AstraZeneca AB
- Country
- Poland (PL)
- ATC code
- L01EE04
- ATC class
- Selumetinib
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05000456070058
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
111 interactions on record for selumetinib.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Selumetinib · interactions on record
111 records
- 30 severe
- 81 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ChloramphenicolJ01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Selumetinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandKoselugoAbacus Medicine A/S
- CanadaKOSELUGOALEXION PHARMA GMBH
- SwitzerlandKoselugo
- CzechiaKOSELUGOAstraZeneca AB, Södertälje
- SpainKOSELUGO 10 mg CAPSULAS DURASAstrazeneca Ab
- FranceKOSELUGO 10 mg, géluleASTRAZENECA AB
- United KingdomKoselugo 10mg capsulesAstraZeneca UK Ltd
- IrelandKoselugo 10 mg hard capsulesAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Koselugo
- Liechtenstein · Koselugo
- Norway · Koselugo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c5e11ff4-e5c5-4630-abcf-6ed8f62e4d68 GET /v1/drugs/c5e11ff4-e5c5-4630-abcf-6ed8f62e4d68?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "10 mg",
"packaging": "05000456070058 ¦ Rpz ¦ EU/1/21/1552/001 ¦ 141066\n60 kaps.",
"substance": "Selumetinibum 10 mg",
"common_name": "Selumetinibum",
"pl_product_id": "100455271",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about selumetinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.